Roivant Sciences Ltd. Common Shares (ROIV)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I ask whether the business produces durable earnings and whether price is supported by assets or earning power. Roivant fails the first test today. In fiscal year 2025, the year ended 2026-03-31, revenue was $8.3M and net loss was $299.8M, or -$0.54 per diluted share. In fiscal year 2024, the year ended 2025-03-31, revenue was $29.1M and net loss was $172.0M. Fiscal year 2023, ended 2024-03-31, showed net income of $4.3B and EPS of $5.23, but that was earlier and not repeated; FairStock labels the stock a TURNAROUND because the latest year had a loss after earlier profits. In fiscal Q1 2026, the quarter ended 2026-06-30, revenue was just $1.4M and net loss was $189.8M. Trailing free cash flow is -$821.1M, so the enterprise consumes cash. The balance sheet has low debt, with D/E of 0.02, and a FairStock Altman Z-Score of 38.12, but a FairStock Piotroski F-Score of 0/9, so quality signals are poor. At the $33.35 close on 2026-10-13 and $24.1B market cap, FairStock calculations show P/B of 5.69, P/E of -70.96, FCF yield of -3.4%, ROE of -8.52%, ROCE of -16.48%, and a FairStock score of 28/100. The moat is not visible from current financials; pipeline assets such as IMVT-1402 and mosliciguat may be differentiated, but no approved-product cash flows are shown here. Valuation rests on pipeline prospects, not reported revenue. I see no margin of safety in reported numbers. A drug developer can create huge value if trials succeed, but that is speculation, not Graham-style investing. I would want proof of commercial traction or cash generation before calling this cheap.

In plain English: Roivant is a drug development company working on medicines for immune and lung conditions. The business looks weak today because sales are tiny, losses are large, and it spends much more cash than it brings in. At the $33.35 close on 2026-10-13, the price looks expensive compared with those current numbers, so much depends on future trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-06-30) · fiscal Q3 2025 10-Q (period ended 2025-12-31) · fiscal Q2 2025 10-Q (period ended 2025-09-30) · fiscal Q1 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2026-03-31) · FY2024 10-K (period ended 2025-03-31) · FY2023 10-K (period ended 2024-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer